Irisin serum levels are positively correlated with bone mineral status in a population of healthy children.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
13
07
2018
accepted:
01
01
2019
revised:
18
12
2018
pubmed:
27
1
2019
medline:
17
6
2020
entrez:
27
1
2019
Statut:
ppublish
Résumé
Irisin is a myokine secreted by skeletal muscle during physical activity. Irisin treatment increased cortical bone mineral density (BMD) in young healthy mice and restored bone and muscle mass loss in a mouse model of disuse-induced osteoporosis and muscular atrophy. In humans, Irisin was positively correlated with BMD in young athletes. Considering that the bone mass reached during childhood is one of the most important determinants of lifelong skeletal health, we sought to determine if Irisin levels were correlated with bone mineral status in children. Irisin and bone metabolic markers were quantified in sera and bone mineral status was evaluated by quantitative ultrasound in a population of 34 healthy children (9.82 ± 3.2 years). We found that Irisin levels were positively correlated with the amplitude-dependent speed of sound Z-score (r = 0.305; p < 0.001), bone transmission time Z-score (r = 0.375; p < 0.001) and osteocalcin (r = 0.370; p < 0.001), and negatively with Dickkopf WNT Signaling Pathway Inhibitor 1 (r = -0.274; p < 0.001). In a regression analysis model, Irisin was one of the determinants of bone mineral status to a greater extent than bone alkaline phosphatase and parathyroid hormone, indicating that Irisin might be considered as one of the bone formation markers during childhood.
Sections du résumé
BACKGROUND
Irisin is a myokine secreted by skeletal muscle during physical activity. Irisin treatment increased cortical bone mineral density (BMD) in young healthy mice and restored bone and muscle mass loss in a mouse model of disuse-induced osteoporosis and muscular atrophy. In humans, Irisin was positively correlated with BMD in young athletes. Considering that the bone mass reached during childhood is one of the most important determinants of lifelong skeletal health, we sought to determine if Irisin levels were correlated with bone mineral status in children.
METHODS
Irisin and bone metabolic markers were quantified in sera and bone mineral status was evaluated by quantitative ultrasound in a population of 34 healthy children (9.82 ± 3.2 years).
RESULTS
We found that Irisin levels were positively correlated with the amplitude-dependent speed of sound Z-score (r = 0.305; p < 0.001), bone transmission time Z-score (r = 0.375; p < 0.001) and osteocalcin (r = 0.370; p < 0.001), and negatively with Dickkopf WNT Signaling Pathway Inhibitor 1 (r = -0.274; p < 0.001).
CONCLUSION
In a regression analysis model, Irisin was one of the determinants of bone mineral status to a greater extent than bone alkaline phosphatase and parathyroid hormone, indicating that Irisin might be considered as one of the bone formation markers during childhood.
Identifiants
pubmed: 30683930
doi: 10.1038/s41390-019-0278-y
pii: 10.1038/s41390-019-0278-y
doi:
Substances chimiques
Biomarkers
0
FNDC5 protein, human
0
Fibronectins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
484-488Références
Boström, P. et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463–468 (2012).
doi: 10.1038/nature10777
Colaianni, G. et al. The myokine irisin increases cortical bone mass. Proc. Natl. Acad. Sci. USA 112, 12157–12162 (2015).
doi: 10.1073/pnas.1516622112
Colaianni, G. et al. Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Sci. Rep. 7, 2811 (2017).
doi: 10.1038/s41598-017-02557-8
Singhal, V. et al. Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates. PLoS ONE 9, e100218 (2014).
doi: 10.1371/journal.pone.0100218
Colaianni, G. et al. Irisin levels correlate with bone mineral density in soccer players. J. Biol. Regul. Homeost. Agents 31(Suppl. 1), 21–28 (2017).
pubmed: 29181953
Klangjareonchai, T. et al. Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. Int. J. Endocrinol. 2014, 261545 (2014).
doi: 10.1155/2014/261545
Palermo, A. et al. Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity. Clin. Endocrinol. (Oxf.) 82, 615–619 (2015).
doi: 10.1111/cen.12672
Anastasilakis, A. D. et al. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporos. Int. 25, 1633–1642 (2014).
doi: 10.1007/s00198-014-2673-x
Faienza, M. F. et al. High irisin levels are associated with better glycemic control and bone health in children with type 1 diabetes. Diabetes Res. Clin. Pract. 141, 10–17 (2018).
doi: 10.1016/j.diabres.2018.03.046
Loomba-Albrecht, L. A. & Styne, D. M. Effect of puberty on body composition. Curr. Opin. Endocrinol. Diabetes Obes. 16, 10–15 (2009).
doi: 10.1097/MED.0b013e328320d54c
Sopher, A. B., Fennoy, I. & Oberfield, S. E. An update on childhood bone health: mineral accrual, assessment and treatment. Curr. Opin. Endocrinol. Diabetes Obes. 22, 35–40 (2015).
doi: 10.1097/MED.0000000000000124
Golden, N. H. & Abrams, S. A. Optimizing bone health in children and adolescents. Pediatrics 134, e1229–e1243 (2014).
doi: 10.1542/peds.2014-2173
Mannocci A. et al. International Physical Activity Questionnaire for Adolescents (IPAQ A): reliability of an Italian version. Miner. Pediatr. https://doi.org/10.23736/S0026-4946.16.04727-7 (2018).
Ogden, C. L., Flegal, K. M., Carroll, M. D. & Johnson, C. L. Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 288, 1728–1732 (2002).
doi: 10.1001/jama.288.14.1728
Tanner, J. M. & Whitehouse, R. H. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch. Dis. Child 51, 170–179 (1976).
doi: 10.1136/adc.51.3.170
Faienza, M. F. et al. High sclerostin and Dickkopf-1 (DKK-1) serum levels in children and adolescents with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 102, 1174–1181 (2017).
pubmed: 28388723
Baroncelli, G. I. et al., Phalangeal Quantitative Ultrasound Group. Cross-sectional reference data for phalangeal quantitative ultrasound from early childhood to young-adulthood according to gender, age, skeletal growth, and pubertal development. Bone 39, 159–173 (2006).
doi: 10.1016/j.bone.2005.12.010
Krieg, M. A. et al. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J. Clin. Densitom. 11, 163–187 (2008).
doi: 10.1016/j.jocd.2007.12.011
Colaianni, G. et al. Irisin enhances osteoblast differentiation in vitro. Int. J. Endocrinol. 2014, 902186 (2014).
doi: 10.1155/2014/902186
Soininen, S. et al. Body fat mass, lean body mass and associated biomarkers as determinants of bone mineral density in children 6-8years of age—The Physical Activity and Nutrition in Children (PANIC) study. Bone 108, 106–114 (2018).
doi: 10.1016/j.bone.2018.01.003
Wren, T. A. et al. Longitudinal tracking of dual-energy X-ray absorptiometry bone measures over 6 years in children and adolescents: persistence of low bone mass to maturity. J. Pediatr. 164, 1280–1285.e2 (2014).
doi: 10.1016/j.jpeds.2013.12.040
Karsenty, G. Update on the biology of osteocalcin. Endocr. Pract. 23, 1270–1274 (2017).
doi: 10.4158/EP171966.RA
Qiao, X. et al. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways. Sci. Rep. 6, 18732 (2016).
doi: 10.1038/srep18732
Kirmani, S. et al. Sclerostin levels during growth in children. Osteoporos. Int. 23, 1123–1130 (2012).
doi: 10.1007/s00198-011-1669-z
Epelak, I. & Čvorišćec, D. Biochemical markers of bone remodeling. Biochem. Med. 19, 17–35 (2009).
doi: 10.11613/BM.2009.003
Ventura, A. et al. Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. Biomed. Res. Int. 2013, 250462 (2013).
doi: 10.1155/2013/250462
Brunetti, G. et al. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α. Osteoporos. Int. 27, 2355–2365 (2016).
doi: 10.1007/s00198-016-3501-2
Brunetti, G. et al. Genotype–phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene. Endocrine 42, 266–271 (2012).
doi: 10.1007/s12020-012-9705-0
Mergler, S., Lobker, B., Evenhuis, H. & Penning, C. Feasibility of quantitative ultrasound measurement of the heel bone in people with intellectual disabilities. Res. Dev. Disabil. 31, 1283–1290 (2010).
doi: 10.1016/j.ridd.2010.07.015
Delvecchio, M. et al. Evaluation of impact of steroid replacement treatment on bone health in children with 21-hydroxylase deficiency. Endocrine 48, 995–1000 (2015).
doi: 10.1007/s12020-014-0332-9
Aceto, G. et al. Bone health in children and adolescents with steroid-sensitive nephrotic syndrome assessed by DXA and QUS. Pediatr. Nephrol. 29, 2147–2155 (2014).
doi: 10.1007/s00467-014-2834-3